AstraZeneca provide insight into biomarkers and personalised treatment at Asthma & COPD 2017
SMi’s 13th annual Asthma & COPD conference returns to London on the 29 and 30 March 2017...
List view / Grid view
SMi’s 13th annual Asthma & COPD conference returns to London on the 29 and 30 March 2017...
Harvard University researchers have developed a multiregional brain-on-a-chip that models the connectivity between three distinct regions of the brain.
Information on significant properties of pharmaceutical tablets, such as their mechanical strength and dissolution, can now be obtained without resorting to the conventional, time-consuming and destructive testing methods, according to a new study completed at the University of Eastern Finland.
The collaboration will combine Immatics’ Xpresident target discovery and T-cell receptor (TCR) capabilities with Amgen’s validated Bispecific T-cell Engager (BiTE) technology with the aim of creating novel oncology drugs.
IDBS has launched the E-WorkBook Cloud, an enterprise, Cloud-based platform designed specifically to meet the future challenges of scientific and R&D data management.
The transaction has been approved unanimously by the boards of directors of both companies, and is expected to close by the end of February 2017.
The USP9 gene has an indirect influence on the so-called tau protein, which is believed to play a significant role in the onset of Alzheimer’s disease.
FDA Present on Regulatory Considerations for Combination Products at Pre-Filled Syringes East Coast this Spring...
BenevolentAI is the first AI company to have a CMO on its staff.
The companies will work together on integrated drug discovery - medicinal and computational chemistry, biology and DMPK - to optimise Chronos’ selective orexin 1 antagonists that have shown promise in treating addiction.
Macrophage Pharma, a newly formed immune-oncology company, has successfully raised £9 million in a Series A equity financing round.
This award recognises outstanding achievements of female researchers in the life sciences in the past five years.
The monoclonal antibody biopharmaceutical group Kymab announced today that it has received a $9m grant from the Bill & Melinda Gates Foundation to accelerate the development of novel vaccines and therapeutics for infectious diseases, including HIV.
In this project, universities and companies across 11 European countries and the US will unite efforts to tailor the development and application of therapies to the individual MS patient.
The outlook for brain tumour patients is pretty negative, with the median survival rate for patients with glioblastoma multiforme, or GBM, a mere 14.2 months.